Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Rhea-AI Summary

Tevogen Bio Holdings (Nasdaq: TVGN) has received $1 million in non-dilutive funding from KRHP LLC to advance Tevogen.AI, its artificial intelligence-powered drug discovery program. This funding is part of a larger $10 million grant agreement, with $2 million already received in January 2025 and potential for an additional $8 million.

The company plans to use the funds to enhance Tevogen.AI's capabilities following the recent patent publication of its machine learning technology for predicting immunologically active peptides. Tevogen maintains strong capitalization with access to a $36 million line of credit, supporting its growth strategy in developing targeted therapies for cancers and infectious diseases.

Positive

• Secured $1 million in non-dilutive funding with potential for additional $8 million
• Access to $36 million line of credit ensuring strong capitalization
• Recent patent publication for proprietary machine learning technology
• Strategic advancement in AI-driven drug discovery capabilities

Negative

• Company has limited operating history
• Needs to raise additional capital to execute business plan
• Faces significant competition in rapidly evolving technological landscape

• Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative.
• The $1 million is part of up to $10 million in previously announced non-dilutive grant funding from KRHP LLC.
• The Company remains well-capitalized, enabling it to fully execute its growth strategy.
  
  

WARREN, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced it has received the previously reported $1 million in funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development program.

The funding is provided through an agreement with KRHP LLC, under which Tevogen received $2 million in January 2025 and may receive up to an additional $8 million, for an aggregate of $10 million in nondilutive funding. KRHP LLC is affiliated with an existing Tevogen investor. Following Tevogen.AI’s recent announcement of the patent publication of its proprietary machine learning technology for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases, the Company plans to use the funding to accelerate Tevogen.AI’s capabilities, enhancing target discovery, shortening development timelines, and improving treatment accessibility for large patient populations.

Tevogen reinforces its operational efficiency and remains well‑capitalized. This funding and its existing agreement which provides access to a $36 million line of credit, ensures it has the resources needed to fully execute its current growth strategy.

Forward-Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: the expected receipt of grant funding from KRHP LLC; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

Communications@Tevogen.com

FAQ

What is the total potential funding Tevogen Bio (TVGN) can receive from KRHP LLC?

Tevogen can receive up to $10 million in total non-dilutive funding from KRHP LLC, with $3 million already received ($2M in January 2025 and $1M recently) and potential for an additional $8 million.

How much funding has Tevogen Bio (TVGN) received for its AI drug discovery program in August 2025?

Tevogen Bio received $1 million in funding in August 2025 to advance Tevogen.AI, its artificial intelligence-powered drug discovery program.

What is Tevogen.AI's recent technological achievement?

Tevogen.AI recently announced the patent publication of its proprietary machine learning technology for predicting immunologically active peptides, crucial for developing targeted cancer and infectious disease therapies.

How well-capitalized is Tevogen Bio (TVGN) in 2025?

Tevogen Bio is well-capitalized with access to a $36 million line of credit and potential for up to $10 million in grant funding from KRHP LLC.

What are the main risks facing Tevogen Bio's growth strategy?

Key risks include the need to raise additional capital, limited operating history, intense market competition, and challenges in keeping pace with rapid technological developments in AI drug discovery.